National Heart, Lung, and Blood Institute
National Institutes of Health
Available Funding and Operating Guidelines
The NHLBI FY2017 Funding and Operating Guidelines apply to all awards made in FY2017. The National Heart, Lung, and Blood Institute (NHLBI) will continue to apply National Institutes of Health (NIH) cost management guidelines when making fiscal year 2017 grant awards (NOT-OD-17-086). Upward adjustments to awarded levels will be considered after FY 2017 appropriations are enacted. Any competing application reviewed in FY17 and considered for funding in FY18 will be funded according to the policies and guidelines for FY18.
The NHLBI funding strategy for competing applications will use one of two methods detailed below, depending upon the specific grant mechanism:
a payline with selective pay
a zone of consideration
The currently available funding strategy information for NHLBI competing awards are displayed in the tables below. The NHLBI will continue to update its funding strategy for FY2017, as necessary and as additional information becomes available. Applicants are advised to use information presented here, in conjunction with information available in their organizational eCommons accounts, for planning purposes only.
Payline with Selective Pay
When a payline is specified, the NHLBI intends to fund all applications equal to or less than the percentile (or priority score if there is no percentile). Depending on the availability of funds, the Institute will make funding decisions on competing applications above the payline, through selective pay actions. The table below details the paylines for relevant grant programs.
|Grant Program Description||Percentile|
Research Project Grant
Early Stage Investigators
Career Development Awards
F31, F32, F33
Pre and Post-doctoral NRSA
Academic Research Enhancement Awards (AREA)
Small Business Innovation Research (SBIR) Grants (Phase I)
Zone of Consideration
A zone of consideration is a range of priority scores within which competing applications will be considered for funding. The table below details the range of priority scores per relevant grant program.
Zone of Consideration
|Grant Program Description|
Zone of Consideration
(Priority Score Range)
|Innovative Research Grants||10 - 30|
|Program Project Grant||10 - 30|
|Institutional NRSA Training||10 - 30|
|Small Business Technology Transfer (STTR) Grants||10 - 40|
|R44||Small Business Innovation Research (SBIR) Grants (Phase II)||10 - 30|
Criteria for Selective Pay and Zone of Consideration
Final award decisions related to selective pay and zones of consideration will be based on a variety of criteria relevant to scientific merit, program balance, and NHLBI strategic priorities including:
Scientific and technical merit of the proposed project, as determined by scientific peer review
National Heart, Lung, and Blood Advisory Council recommendations
Relevance to NHLBI’s strategic research priorities (http://www.nhlbi.nih.gov/sites/www.nhlbi.nih.gov/files/020316DSRPPublicCommentVersion-FINALB.pdf)
Overall programmatic portfolio balance and need (e.g., scientific gaps and needs, areas of interest to the NHLBI, poorly represented areas in Institute’s portfolio, overlap with existing programs, etc.)
Development and diversity of biomedical workforce (e.g., investigator’s career stage, etc.)
Potential for high scientific or public health impact (e.g., highly innovative research, research relevant to special populations that are disproportionately affected or understudied [women, minorities, pediatric populations, patients with rare diseases], etc.)
Future Year Commitments on FY 2017 New and Competing Renewal Awards:
As in recent fiscal years (see NOT-OD-13-064), inflationary increases for future year commitments are no longer provided for all competing and non-competing research grant awards issued by the NHLBI. However, adjustments for special needs (such as equipment and added personnel) continue to be accommodated whenever possible.
Duration of Research Project Grants
The NHLBI will fund investigator-initiated R01 competing applications, regardless of percentile or priority score, for up to four years. The only exceptions to this policy are awards made to Early Stage Investigators (ESIs) and clinical trials with patient accrual and follow-up timelines that cannot be accomplished within four years. These excepted applications will generally be awarded for the full length of their National Heart, Lung, and Blood Advisory Council (NHLBAC) recommended project periods.
Early Stage Investigators
Fostering the success of Early Stage Investigators (ESIs) who are establishing careers in biomedical research is a high priority of the NHLBI and NIH, and the NHLBI will continue its commitment to ESIs in accordance with NIH guidelines as articulated in the NIH Guide (see NOT-OD-09-013). The NHLBI commitment to ESIs is reflected in the special consideration given in both funding priority and period of support. Funding advantage is given to ESI applications from Principal Investigators who maintain New Investigator (NI) status when a funding decision is made.
The NHLBI routinely considers funding ESI applications that score outside of the normal funding range by maintaining a separate payline for competing, investigator-initiated ESI R01 applications. In FY 2017, the payline for these applications will be 10 percentile points above the regular R01 payline. Further, all awards to ESI applicants that are included under that policy will be funded for all years recommended by the NHLBAC.
Note regarding NHLBI policy on ESI application resubmission post ESI eligibility status: For investigators whose ESI eligibility window expires between the new (A0) application submission and the resubmission (A1), the NHLBI will honor ESI special funding consideration for these resubmission applications for the entirety of the resubmission window (37 months). In other words, provided an ESI submits the original application and maintains NIH New Investigator Status, the resubmission (A1) of these applications is eligible for NHLBI ESI special funding consideration. Note that the NHLBI approach differs from the NIH statement about retaining ESI-eligible status for investigators whose ESI eligibility window expires between the original submission and resubmission by extending the 13- month resubmission window (please see FAQ 7) to 37 months.
Note regarding applications with Multiple PIs: To be eligible for the ESI funding advantage, all PIs on multiple-PI applications must originally have been ESIs and maintain a New Investigator status when a funding decision is made.
Note regarding phased mechanisms/transitional grants: The ESI funding advantage applies to phased mechanisms/transitional grants. However, note that upon transition to the second phase of the research (the substantial, independent research grant) the New Investigator status for the PD/PI(s) will no longer apply. This includes combined, transitional awards like the R21/R33, SBIR/STTR Fast-Track (R42, UT2, R44, U44), UH2/UH3.
First Competing Renewals (Type 2) or New (Type 1) R01 Application for Investigators with an NHLBI Early Stage Investigator Award
The NHLBI appreciates that the first competing renewal application or second R01 application at the end of an awarded ESI applications are submitted during a critical period in investigators’ careers. In order to extend timely support for the next generation of heart, lung, blood, and sleep researchers, the NHLBI maintains a separate payline of 5 percentile points above the regular R01 payline for investigator-initiated first competing renewal (Type 2) or secondary new (Type 1) R01 applications that meet all of the following criteria:
the initial (Type 1) application was funded as an NHLBI ESI application and is currently in the last project period year or within two fiscal years beyond the last project period year
the individual is not and has not been a principal investigator on an Independent Scientist (K02) or other non-mentored career award, on another R01, or on any other “major award” mechanism that disqualifies one from being considered an NIH New Investigator (see http://grants.nih.gov/grants/new_investigators/index.htm#earlystage)
the application must be from a domestic institution
Note: This is a special NHLBI program, therefore the competing renewal applications will not be flagged by the NIH grant system. Rather, NHLBI staff will identify applications eligible for special funding consideration under this Program. Further, to be eligible for this funding advantage, all PIs on multiple-PI applications must meet the criteria described above.
NHLBI Interim Funding Using the R56 (High Priority, Short-Term Project) Award
Pending the availability of funds, the NHLBI may use the R56 grant mechanism, sometimes called "Bridge Award," to provide limited, interim research support to competing R01 applications requesting less than $500K in direct costs per year. Eligible investigators cannot have substantial funding support from within or outside the NIH beyond the current fiscal year. Further, applications with administrative issues that preclude timely award are ineligible for this program. NHLBI participation in the R56 mechanism was published in the NIH Guide (see NOT-HL-13-188). Please note that investigators cannot apply for R56 awards.
The ultimate goal of the award is to provide interim, one-year support for investigators to collect preliminary data in support of a resubmission or newly competing NIH R01 application.
The NHLBI will use the following guidelines for funding RPGs:
The FY2017 salary cap for individuals under an NIH grant or cooperative agreement is established by statute at $187,000 effective January 8, 2017 (NOT-OD-17-049).
Competing (Type 1 and Type 2) Research Project Grant Awards
The NHLBI policy for competing grants is to award them at the NHLBAC recommended level except for specific programmatic and administrative adjustments. Applications that do not exceed $250,000 direct costs in any given year of support in the recommended competitive segment are generally awarded under the modular concept. Applications requesting direct costs that exceed $250,000 in any year of support in the recommended competitive segment will be awarded with categorical budgets.
Effective FY17, NHLBI is no longer limiting Type 2 awards to NHLBAC recommended direct costs plus a maximum of three percent above the level of the last noncompeting segment.
Program Project Grants (Type 1 and Type 2)
Type 1: Direct costs will be awarded at the recommended level or $1,515,000, whichever is less. Facilities and Administrative (F&A) Costs associated with first tier subcontracts are not included in the direct cost ceiling. No annual increases for recurring costs in non-competing years are allowed.
Type 2: Direct costs (excluding first tier subcontract F&A costs) awarded will not exceed the direct costs (excluding first tier subcontract F&A costs) for the last noncompetitive segment. As with new awards, no annual increases for recurring costs are allowed.
Effective FY17, all new (Type 1) and renewal (Type 2) Program Project Grant (P01) competing applications will be awarded at or below the NHLBI published Program Project Grants (P01s) direct costs cap (excluding first-tier subcontract Facilities and Administrative [F&A] costs) for each project year, in accordance with the PPG cap policy. No annual increases in noncompeting years may be requested. Equipment is included in the budget ceiling.
Continuation Awards (Type 5 Noncompeting Renewal)
The NHLBI will award Type 5 grants in accordance with the NIH Fiscal Policy for FY2017.
Last Updated: August 31 2017